News
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.
BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...
Zacks Investment Research on MSN2d
NVAX Stock Surges on Securing FDA Approval for COVID-19 VaccineShares of Novavax NVAX surged nearly 26% in pre-market trading today after its protein-based COVID-19 vaccine, Nuvaxovid, ...
Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market ...
JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...
Stocktwits on MSN1d
FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks RiseThe U.S. Food and Drug Administration (FDA ) leaders said on Tuesday they would adopt a new COVID-19 vaccination regulatory ...
Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback